Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Healthcare
Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Acasti Pharma Inc > Don’t waste your Time replying to posters like Boozehound
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by boozehound3on Jun 01, 2019 12:57pm
44 Views
Post# 29791289

RE:Don’t waste your Time replying to posters like Boozehound

RE:Don’t waste your Time replying to posters like Boozehound

DID YOU EVEN READ THAT ARTICLE? PROBALY NOT    IF FDA ASKES AMARIN FOR ANOTHER TRIAL IT WILL BE OVER FOR THE ENTIRE SECTOR AND BEST IN CLASS WON'T MATTER.

PLEASE OFFER SOMETHING OTHER THAN HOPE AND PRAYER. DO SOME DUE DILLAGANCE!

I DON'T NEED NOR WANT ANY MORE SHARES OF THIS OUTFIT THERE IS PLENTY FOR SALE!

I GOT SUCKED INTO THIS THING AND HAVE BEEN STUCK LIKE THE REST OF YOU.
I AM ONLY PROVIDING YOU ALL WITH REASONS WHY THIS WILL GO NOWHERE

CHOOSING NOT TO LISTEN AND JUST CROSSING YOUR FINGERS IN NOT GOOD INVESTING

IF YOU READ THAT ARTICLE GIVE ME A REBUTTAL TO IT.  IT IS VERY CONCERNING AND IS THE REASON AMARIN HASN'T BEEN SOLD YET.  IT IS THE REASON THERE IS NO INTERST IN ACASTI AS WELL.

I BET YOU DON'T EVEN UNDERSTAND IT BLAIRMAN

SAY SOMETHING INTELLIGENT FOR ONCE
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities